PALISADE BIO, INC. (PALI)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$132.6M
Cash & Equivalents
$3.9M
Quarterly Burn Rate
102 mo
Est. Cash Runway
$340M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07428096 A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's D... PHASE1 Active Not Recruiting 6

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for PALI.

SEC EDGAR Filings

All SEC filings for PALISADE BIO, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.